Skip to Content

BiDil Side Effects

Generic Name: hydralazine / isosorbide dinitrate

Note: This page contains information about the side effects of hydralazine / isosorbide dinitrate. Some of the dosage forms included on this document may not apply to the brand name BiDil.

Not all side effects for BiDil may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

For the Consumer

Applies to hydralazine / isosorbide dinitrate: oral tablet

If you experience any of the following serious side effects, stop taking hydralazine and isosorbide dinitrate and seek emergency medical attention:

  • an allergic reaction (difficulty breathing; closing of your throat; swelling of your lips, tongue, or face; or hives);

  • blurred vision and dry mouth;

  • irregular heartbeat; or

  • blood in your urine or stools;

  • numbness, tingling, pain, or weakness of your arms or legs;

  • fainting.

Other, less serious side effects may be more likely to occur. If you experience any of the following side effects, continue to take isosorbide and talk to your doctor:

  • headache or dizziness;

  • flushing (redness of the face, neck and chest);

  • nausea or vomiting;

  • fast heartbeat;

  • swollen ankles; or

  • weakness.

Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome.

For Healthcare Professionals

Applies to hydralazine / isosorbide dinitrate: oral tablet

General

The most common side effects were headache, dizziness, asthenia, and nausea.[Ref]

Nervous system

Very common (10% or more): Headache (50%), dizziness (32%)
Common (1% to 10%): Paresthesia
Postmarketing reports: Tinnitus, dysgeusia, hypoesthesia, migraine, syncope[Ref]

Other

Very common (10% or more): Asthenia (14%)
Postmarketing reports: Vertigo, facial pain, chest discomfort, chest pain, peripheral edema[Ref]

Gastrointestinal

Very common (10% or more): Nausea (10%)
Common (1% to 10%): Vomiting
Postmarketing reports: Abdominal discomfort, constipation[Ref]

Cardiovascular

Common (1% to 10%): Hypotension, ventricular tachycardia
Postmarketing reports: Palpitations, flushing[Ref]

Ocular

Common (1% to 10%): Amblyopia
Postmarketing reports: Eyelid edema, vision blurred[Ref]

Respiratory

Common (1% to 10%): Sinusitis
Postmarketing reports: Dyspnea[Ref]

Dermatologic

Postmarketing reports: Erythema, hyperhidrosis, pruritus, face swelling[Ref]

Genitourinary

Postmarketing reports: Chromaturia, erectile dysfunction[Ref]

Musculoskeletal

Postmarketing reports: Pain in extremity, myalgia[Ref]

Renal

Postmarketing reports: Pulmonary renal syndrome[Ref]

References

1. "Product Information. BiDil (hydralazine-isosorbide dinitrate)." NitroMed Inc, Lexington, MA.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.

Hide